Abivax S.A. Research and Development Expense
Abivax S.A. (ABVX) reported Research and Development Expense of EUR 177.76 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-23
- Abivax S.A. research and development expense for the quarter ending 2025-12-31 was 44.40M EUR, a 15.04% increase year-over-year.
- Abivax S.A. research and development expense for the quarter ending 2025-09-30 was 55.42M EUR, a 28.02% increase year-over-year.
- Abivax S.A. research and development expense for the quarter ending 2025-06-30 was 38.65M EUR, a 33.69% increase year-over-year.
- Abivax S.A. research and development expense for the quarter ending 2025-03-31 was 39.30M EUR, a 9.95% increase year-over-year.
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | 44.40M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-23 | 99.81M EUR derived: sum of 2 quarters · filed 2026-03-23 | 138.46M EUR derived: sum of 3 quarters · filed 2026-03-23 | 177.76M EUR 20-F · filed 2026-03-23 |
| 2025-09-30 | 55.42M EUR 6-K · filed 2025-12-15 | 94.06M EUR derived: sum of 2 quarters · filed 2025-12-15 | 133.36M EUR 6-K · filed 2025-12-15 | 171.96M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-06-30 | 38.65M EUR 6-K · filed 2025-09-08 | 77.95M EUR 6-K · filed 2025-09-08 | 116.54M EUR derived: sum of 3 quarters · filed 2026-03-23 | 159.83M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-03-31 | 39.30M EUR 6-K · filed 2025-06-02 | 77.90M EUR derived: sum of 2 quarters · filed 2026-03-23 | 121.18M EUR derived: sum of 3 quarters · filed 2026-03-23 | 150.09M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-12-31 | 38.60M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-23 | 81.88M EUR derived: sum of 2 quarters · filed 2026-03-23 | 110.79M EUR derived: sum of 3 quarters · filed 2026-03-23 | 146.53M EUR 20-F · filed 2026-03-23 |
| 2024-09-30 | 43.29M EUR 6-K · filed 2025-12-15 | 72.19M EUR derived: sum of 2 quarters · filed 2025-12-15 | 107.94M EUR 6-K · filed 2025-12-15 | |
| 2024-06-30 | 28.91M EUR 6-K · filed 2025-09-08 | 64.65M EUR 6-K · filed 2025-09-08 | ||
| 2024-03-31 | 35.74M EUR 6-K · filed 2025-06-02 | |||
| 2023-12-31 | 103.18M EUR 20-F · filed 2026-03-23 | |||
| 2022-12-31 | 48.30M EUR 20-F · filed 2025-03-24 | |||
| 2021-12-31 | 47.78M EUR 20-F · filed 2024-04-05 |